Claim Details

View detailed information about this claim and its related sources.

Claim Information

Complete details about this extracted claim.

Claim Text: Fifty-nine percent of respondents said they used psilocybin for "fun," e.g., "for a sense of joy, pleasure, or play, including at a party or other social gathering."
Simplified Text: 59% used psilocybin for fun.
Confidence Score: 0.800
UUID: d57ccc94-c4be-45ca-91e3-6c28e763f23c
Vector Index: ✗ No vector
Created: December 6, 2025 at 12:39 AM (8 months ago)
Last Updated: December 6, 2025 at 12:39 AM (8 months ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://reason.com/2025/11/12/the-perils-of-viewing-psilocybin-strictly-as-a-psychiatric-medication

https://reason.com/2025/11/12/the-perils-of-viewing-psilocybin-strictly-as-a-psy...

Completed

18 claims 🔥

1 week ago

https://reason.com/2025/11/12/the-perils-of-viewing-psilocybin-strictly-as-a-psychiatric-medication

Similar Claims (5)

Other claims identified as semantically similar to this one.

In a 2023 RAND Corporation survey of people who had used psilocybin in the last year, 49 percent described their goal as "improved mental health," a category that includes but extends beyond individua... 0.800

Simplified: 49% used psilocybin for mental health in a 2023 RAND survey.

8 months ago
Five years ago, Oregon voters took a different approach, approving a ballot initiative that authorized state-licensed "psilocybin service centers" where adults 21 or older can use the drug under the s... 0.900

Simplified: Oregon voters approved psilocybin service centers five years ago.

8 months ago
SRI President Sue Sisley says she aims to explore the possibility that other components of psilocybin mushrooms contribute to their effects. 0.900

Simplified: Sue Sisley wants to study other psilocybin components.

8 months ago
In 2018, the FDA recognized psilocybin as a "breakthrough therapy" for "treatment-resistant depression," a designation that was supposed to facilitate regulatory approval. 0.900

Simplified: FDA designated psilocybin a 'breakthrough therapy' in 2018.

8 months ago
Other common responses included "personal development" (45 percent), "curiosity" (43 percent), "spiritual growth" (41 percent), and "cognitive development" (41 percent). 0.800

Simplified: Other psilocybin use motives: personal development, curiosity, etc.

8 months ago